Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US11103517 | EPI HLTH | Pharmaceutical compositions for minocycline |
Apr, 2036
(13 years from now) |
Drugs and Companies using MINOCYCLINE HYDROCHLORIDE ingredient
Market Authorisation Date: 08 May, 2017
Treatment: NA
Dosage: TABLET, EXTENDED RELEASE;ORAL
2
United States
1
IB
1
India
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8815929 | EPI HLTH | Method and therapeutic/cosmetic topical compositions for the treatment of rosacea and skin erythema using α1-adrenoceptor agonists |
Jan, 2024
(10 months from now) | |
US8420688 | EPI HLTH | Method and therapeutic/cosmetic topical compositions for the treatment of rosacea and skin erythema using α1-adrenoceptor agonists |
Aug, 2024
(1 year, 4 months from now) | |
US7812049 | EPI HLTH | Method and therapeutic/cosmetic topical compositions for the treatment of rosacea and skin erythema using α1-adrenoceptor agonists |
May, 2028
(5 years from now) | |
US8883838 | EPI HLTH | Pharmaceutical cream compositions and methods of use |
Dec, 2031
(8 years from now) | |
US10335391 | EPI HLTH | Stabilized oxymetazoline formulations and their uses |
Jun, 2035
(12 years from now) | |
US10751325 | EPI HLTH | Stabilized oxymetazoline formulations and their uses |
Jun, 2035
(12 years from now) | |
US9974773 | EPI HLTH | Stabilized oxymetazoline formulations and their uses |
Jun, 2035
(12 years from now) | |
US11517560 | EPI HLTH | Stabilized oxymetazoline formulations and their uses |
Jun, 2035
(12 years from now) |
Drugs and Companies using OXYMETAZOLINE HYDROCHLORIDE ingredient
Market Authorisation Date: 18 January, 2017
Treatment: Topical treatment of persistent facial erythema associated with rosacea in adults with 1% oxymetazoline hydrochloride cream; Once daily topical treatment of persistent facial erythema associated with rosacea in adults with 1% oxymetazoline hydrochloride cream, where the patient experiences no rebound or worsening of facial erythema post-treatment; Once daily topical treatment of persistent facial erythema associated with rosacea in adults; Once daily topical treatment of persistent facial erythema associated with rosacea in adults with 1% oxymetazoline hydrochloride cream; Once daily topical treatment of persistent facial erythema associated with rosacea in female adults
Dosage: CREAM;TOPICAL
26
United States
4
Australia
3
Spain
3
European Union
2
Canada
1
Taiwan, Province of China
1
Portugal
1
Hong Kong
1
Poland
1
Denmark
1
Mexico
1
Japan
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8791127 | EPI HLTH | Mucosal bioadhesive slow release carrier for delivering active principles |
Mar, 2027
(4 years from now) | |
US8747896 | EPI HLTH | Mucosal bioadhesive slow release carrier for delivering active principles |
Jun, 2027
(4 years from now) | |
US8592434 | EPI HLTH | Mucoadhesive buccal tablets for the treatment of orofacial herpes |
Jun, 2030
(7 years from now) |
Drugs and Companies using ACYCLOVIR ingredient
Market Authorisation Date: 12 April, 2013
Treatment: Treatment of herpes labialis
Dosage: TABLET;BUCCAL
8
United States
7
European Union
2
Portugal
2
Spain
2
Croatia
2
China
2
Japan
2
Canada
2
Poland
2
RS
2
Denmark
1
Germany
1
Turkey
1
Malaysia
1
Russia
1
Brazil
1
IB
1
New Zealand
1
Argentina
1
Austria
1
Mexico
1
Korea, Republic of
1
Hong Kong
1
South Africa
1
Cyprus
1
Hungary
1
ME
1
Slovenia
1
Israel
1
Australia
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic